ESR1 and neoplasm: In the group of estrogen receptor negative samples, we evaluated whether a previously reported stroma-related gene signature would predict resistance [7], however, in the present series of microdissected stromal cells, this gene profile could not separate resistant from responsive samples (pathological complete response or tumor downstaging), and a common pattern of gene expression could be distinguished.